KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2025)

Gilead Sciences' Asset Writedowns and Impairment history spans 5 years, with the latest figure at $400.0 million for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $400.0 million; the TTM value through Dec 2025 reached $590.0 million, down 85.95%, while the annual FY2025 figure was $590.0 million, 85.89% down from the prior year.
Asset Writedowns and Impairment reached $400.0 million in Q4 2025 per GILD's latest filing, up from $190.0 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $2.7 billion in Q1 2022 to a low of $50.0 million in Q4 2023.
Average Asset Writedowns and Impairment over 4 years is $1.3 billion, with a median of $1.1 billion recorded in 2024.